Lung Shield ‘Program’ provides clients with compassionate use of cellular therapy coverage for post COVID-19 Lung Infection Recovery.

In support of the national vaccination program, all clients of Lung Shield will also be provided a complimentary post COVID-19 vaccine complication cover and accidental death benefits.

Cellular therapy is clinically proven to be effective in the field of regenerative medicine and holds promising potential in treating lung damage inflicted by Covid-19.

Lung Shield only uses stem cells produced under current Good Manufacturing Practice (cGMP).

Only RM 2.70 / Day*

CELLULAR COVERAGE:

Cellular therapy for lung damage caused by post Covid-19 infection (Up to 40 million Mesenchymal Stem Cells)
Pre cellular therapy health screening
Lung function testUnderwritten by: The Pacific Insurance Berhad

PERSONAL ACCIDENT INSURANCE:

Accidental death RM5,000
Accidental permanent disablement RM5,000Underwritten by: The Pacific Insurance Berhad

POST COVID-19 VACCINATION COVERAGE:

Daily Hospital Income Benefit at RM400 per day up to RM5,600
A lump sum benefit of RM4,000 for Intensive Care Unit (ICU) admission
Bereavement expense benefit up to RM10,000
Accidental death RM10,000

Underwritten by: Chubb Insurance Malaysia Berhad

SURVEILLANCE INCLUDED:

Free initial RT-PCR Test
Free Functional Neutralising Total Antibody Test (Check your immunity levels towards Covid-19!)* Limited to 2 persons per family package

E&OE and T&Cs apply

The Pacific Insurance Berhad (“TPIB”) and Chubb Insurance Malaysia Berhad (“Chubb”) are licensed under the Financial Services Act 2013 and are regulated by Bank Negara Malaysia.

Add To Cart

RM1,799 Annually

Husband & Wife: RM1,799.00

Husband, Wife & Child: RM2,399.00

Husband, Wife & Children: RM2,999.00

Single Mum/Dad & Child: RM1,799.00

Single Mum/Dad & Children: RM2,399.00

✓Surveillance Benefits limited up to two (2) persons per family package. Additional members of the family will be charged at the rate of RM 300 per pax

Add To Cart

Only child / children not exceeding the age of 21 years old will be entitled to join as Family Client (except for students in full time tertiary education).

Tailor-made

ENQUIRE NOW

With Negative RT-PCR Test results within 48 hours prior to application (testing costs are inclusive in the program)

Open to all ages

Open to all with pre existing conditions or comorbidities (except with cancer, Lung related illness & previously Covid-19 positive)

Open to all citizens and permanent residents of Malaysia only

Vaccinated with at least one (1) dose

Is it safe?

Cellular Therapy is less immunogenic. It lowers the risks of rejection by the individual’s immune system and complications when transplanted.

Homing Ability

Cellular Therapy possesses a unique homing ability. Once transplanted, the cells are naturally directed to the damaged tissues which are in need of repair and replacement.

CATEGORY1

Asymptomatic (does not require any treatment).Only RT-PCR is positive

CATEGORY2

Symptomatic, no pneumonia. Upper respiratory tract (URT) symptoms (e.g. pharyngeal congestion, sore throat, cough or fever) for a period less than 7 days

CATEGORY3

Symptomatic, with pneumonia. URTI symptoms with others like vomiting, diarrhoea, abdominal pain, myalgia, lost of smell/taste. Signs of increase work of breathing and increase respiratory rate,but no hypoxemia

CATEGORY4

Symptomatic, pneumonia requiring oxygen supplementation. Tachyphonea* with hypoxemia(Sp02 94% on room air)

CNS effect: Lethargy, decreased level of consciousness, seizure
GI effects: Dehydration, difficulty feeding, raised liver enzymes
Myocardial effect: Raised Creatinine Kinase, Troponin

CARTEGORY5

Critically ill with multiple organ involvement.

Respiratory failure requiring mechanical ventilation(acute respiratory distress syndrome – ARDS)
Presistent hypoxemia
Septic shock
Organ failure

Post Covid-19 Lung Conditions

Generally, patients recover within weeks from Covid-19 infection but some unfortunately experience “Post Covid-19 Lung Infection’, also known as “Long Covid” especially from the assault of the new variants and cytokines storm.

Some may even experience conditions consisting of multiorgan effects that lasts for months after infection.

(https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html)

Repair & regenerate damaged cells

Anti-inflammatory Actions

Reduces Oxidative Stress

Tissue Repair/ Renovation

Antimicrobial Action

Is it an effective treatment for post Covid-19 lung damage?

Cellular therapy possesses immunomodulatory properties. They have been shown to reduce inflammatory markers in several studies.

Recent Clinical Trials show that cellular therapy reduces the risk of complications and death in SARS-CoV-2 infected patients. They help to improve the microenvironment, promote neovascularisation, inhibit pulmonary fibrosis and enhance tissue repair capabilities.

Is it an approved treatment?

Generally all stem cell products require FDA approval. Currently, the only stem cell products that are FDA-approved for use in the United States consist of blood forming stem cells also known as (hematopoietic progenitor cells) that are derived from the umbilical cord blood. These products are approved for use in patients with disorders that affect the production of blood.

In April 2020, the U.S. Food and Drug Administration (FDA) authorized a clinical trial exploratory efficacy study that used umbilical cord-derived MSCs for prevention of the life-threatening lung inflammation in COVID-19 patients.

Stem cells should only be used in FDA-approved clinical trials, expanded access program, or an Emergency Investigation New Drug application and for compassionate use.

Medical Journals and News on effectiveness

Journals

News

Cellular Therapy Coverage for Post Covid-19 Lung Infection